Even after the pandemic had an adverse effect on Wall Street and the global stock market some of the pharma stocks are still showing the bullish signal. Below is the list of 3 best stocks to buy in May 2020

The stocks on Wall Street posed a major downfall as more than 30 million US residents filed for unemployment benefits over the past few weeks due to the pandemic. The Dow Jones dropped 288.14 points to close at 24,345.72 levels. Also, other major Indices followed the same. On the other hand, global stocks followed the bearish trend, where European Indices such as CAC40 and FTSE100 closed in the red.

We see a major change in the trend after a boom in tech stocks last month. This month the stocks pick will be different as the tech stocks already are in overbought zone considering the market overall. Not every discounted stock is a good buy! Some of the stock hits a higher level, but some still remain attractive to buy for the long-term investment. Below is the list of 3 best stocks to invest in May 2020 for long-term goals.


1. Gilead Sciences

Gilead Sciences Inc. made an announcement for the result of the trial of medicine that can fight with CIVID-19. The company is based in the USA and is a major drug production company that has invented the cure for hepatitis-C before.

Coming to the fundamentals of the company, we see a major drop in EPS from the past few quarters. Indeed this isn’t a good sign for the investment point of view. In Q1 2020, the company showed a 1 percent earning gain, however, the sales figures show a rise of 5 percent to $5.5B and beat the prediction by 10 percent.


2. GlaxoSmithKline

Following the race to combat coronavirus the pharma giant – GSK also jumped into the race and started working on a vaccine. The shares of the company surged 14.8% over the past 30 days.

The company made a huge investment in 2020 to develop the vaccine. GSK has been showing good numbers when it comes to sales and is growing quarter by quarter.


3. Heat Biologics

Heat Biologics has announced that it is working in collaboration with Miller School of Medicine to compact COVID-19.

The shares of the company surged more than 3 percent on the last trading session, reaching $0.6 price per share at press time. Heat Biologics represents 79 million in outstanding shares, while it has a total market valuation of around $47 million.